IL‐15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis

Shimizu, Toshimasa; Koga, Tomohiro; Furukawa, Kaori; Horai, Yoshiro; Fujikawa, Keita; Okada, Akitomo; Okamoto, Momoko; Endo, Yuichi; Tsuji, Sosuke; Takatani, Ayuko; Umeda, Masataka; Fukui, Shoichi; Sumiyoshi, Remi; Kawashiri, Shin‐ya; Iwamoto, Naoki; Isobe, Takashi; Ichinose, Kunihiro; Tamai, Mami; Sakamoto, Noriho; Nakamura, Hideki; Origuchi, Tomoki; Mukae, Hiroshi; Kuwana, Masataka; Kawakami, Atsushi

doi:10.1111/joim.13154

Cited by 36 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moneta et al showed that tumor necrosis factor (TNF) expression was significantly increased in DM patients prior to glucocorticoid therapy (22). Interleukin-6 (IL-6), interleukin-17A (IL-17A), and interleukin-15 (IL-15) have also been implicated in DM progression (23)(24)(25). IL-15 has been identified as a crucial biomarker for predicting the development of rapidly progressive interstitial lung disease in DM/PM patients (25).…”

Section: Discussionmentioning

confidence: 99%

“…Interleukin-6 (IL-6), interleukin-17A (IL-17A), and interleukin-15 (IL-15) have also been implicated in DM progression (23)(24)(25). IL-15 has been identified as a crucial biomarker for predicting the development of rapidly progressive interstitial lung disease in DM/PM patients (25). These findings show that cytokine and type I interferon signaling pathway changes are key events in the onset and progression of DM.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Autophagy-related genes are potential diagnostic biomarkers for dermatomyositis

Wang¹,

Fang²,

Liu³

2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Autophagy-related genes are potential diagnostic biomarkers for dermatomyositis

Wang¹,

Fang²,

Liu³

2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…Some studies have assessed whether BAL cellular makeup can predict outcome in patients with different ILD subtypes, but results have had mixed (188)(189)(190)(191). BAL protein biomarkers, including YKL-40, IL-15, IL-2, and TNF have been linked to differential survival in various ILD subtypes (101, 150,192), but these studies have been generally limited by small sample sizes. Airway biomarkers of near-term FVC function decline are also limited, but BAL interferon gamma and transforming growth factor beta may predict progressive RA-ILD (193).…”

Section: Prognosticmentioning

confidence: 99%

Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response

2021

View full text Add to dashboard Cite

Interstitial lung disease (ILD) comprises a heterogenous group of diffuse lung disorders that commonly result in irreversible pulmonary fibrosis. While idiopathic pulmonary fibrosis (IPF) is the prototypical progressive fibrosing ILD (PF-ILD), a high proportion of patients with other ILD subtypes develop a PF-ILD phenotype. Evidence exists for shared pathobiology leading to progressive fibrosis, suggesting that biomarkers of disease activity may prove informative across the wide spectrum of ILDs. Biomarker investigation to date has identified a number of molecular markers that predict relevant ILD endpoints, including disease presence, prognosis, and/or treatment response. In this review, we provide an overview of potentially informative biomarkers in patients with ILD, including those suggestive of a PF-ILD phenotype. We highlight the recent genomic, transcriptomic, and proteomic investigations that identified these biomarkers and discuss the body compartments in which they are found, including the peripheral blood, airway, and lung parenchyma. Finally, we identify critical gaps in knowledge within the field of ILD biomarker research and propose steps to advance the field toward biomarker implementation.

show abstract

“…In addition to this, Myofascia-dominant involvement, elevated CRP, decreased lymphocyte count, elevated Soluble CD206, elevated interleukin-15 (IL-15), elevated carcinoembryonic antigen, and prolonged activated partial thromboplastin time (aPTT) ratio are also risk factors for the development of RP-ILD in DM patients. [10][11][12][13][14][15] High plasma ferritin levels, generalized worsening of pulmonary infiltrates, ground glass shadow, and elevated serum neopterin levels are significantly associated with reduced survival in DM patients with RP-ILD. 16,17 Studies on RP-ILD associated with juvenile DM, on the other hand, found that IL-18, KL-6, ferritin and anti-MDA5 antibodies were associated with RP-ILD.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease

Wang¹,

Tian²,

Liu³

et al. 2022

PGPM

View full text Add to dashboard Cite

Background Rapidly progressive interstitial lung disease (RP-ILD) is a significant complication that determines the prognosis of dermatomyositis (DM). Early RP-ILD diagnosis can improve screening and diagnostic efficiency and provide meaningful guidance to carry out early and aggressive treatment. Methods A retrospective screening of 284 patients with DM was performed. Clinical and laboratory characteristics of the patients were recorded. The risk factors of RP-ILD in DM patients were screened by logistic regression (LR) and machine learning methods, and the prediction models of RP-ILD were developed by machine learning methods, namely least absolute shrinkage and selection operator (LASSO), random forest (RF), and extreme gradient boosting (XGBoost). Results According to the result of univariate LR, disease duration is a protective factor for RP-ILD, and ESR, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are risk factors for RP-ILD. The top 10 important variables of the 3 machine learning models were intersected to obtain common important variables, and there were 5 common important variables, namely disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody. The AUC of LASSO, RF and XGBoost test set were 0.661, 0.667 and 0.867, respectively. We further validated the performance of these three models on validation set, and the results showed that, the AUC of LASSO, RF and XGBoost were 0.764, 0.727 and 0.909, respectively. Based on the results of the models, XGBoost is the optimal model in this study. Conclusion Disease duration, LDH, CRP, anti-Ro-52 antibody and anti-MDA5 antibody are vital risk factors for RP-ILD in DM. The prediction model constructed using XGBoost can be used for risk identification and early intervention in DM patients with RP-ILD and practical application.

show abstract

IL‐15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis

Cited by 36 publications

References 35 publications

Autophagy-related genes are potential diagnostic biomarkers for dermatomyositis

Autophagy-related genes are potential diagnostic biomarkers for dermatomyositis

Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response

Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease

Contact Info

Product

Resources

About